IP Library Granted Patent US 10,004,790
Granted Patent B2
US 10,004,790 · App. 14/874,978 · Granted Jun 26, 2018

Nanospheres encapsulating bioactive material and method for formulation of nanospheres

Inventor: Martin J. D'Souza (Duluth, GA)
Assignee: THE CORPORATION OF MERCER UNIVERSITY
A61K39/00A61K9/0021A61K9/1629A61K9/5161A61K9/5169A61K9/5192A61K31/245A61K31/46A61K31/5383A61K31/7036A61K31/7048A61K31/7088A61K31/727A61K39/0008A61K39/095A61K39/155A61K39/165A61K39/39C12N7/00C12N15/88A61K48/00A61K2039/52A61K2039/54A61K2039/55555A61K2039/55594A61K2039/57C12N2760/18434C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,790
App. No.
14/874,978
Granted
Jun 26, 2018
Kind
B2
Abstract

A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.

Claims (6)

1. A method of transdermal delivery of a vaccine, comprising:

(a) preparing a polymeric solution comprising a nonorganic solvent, and at least two polymers selected from the group consisting of hydroxyl-propyl methylcellulose acetate succinate, cellulose acetate phthalate polymer (CAP), ethyl cellulose, HPMC-AS, Eudragit® FS30D, and chitosan glycol;

(b) preparing microparticles of encapsulated vaccine by spray drying at a temperature higher than the boiling point of the solvent and lower than the temperature at which the vaccine degrades a mixture of a proteinaceous vaccine material and the polymeric solution;

(c) providing at least one microneedle;

(d) introducing the microparticles into the at least one microneedle; and,

(e) injecting the microparticles transdermally through the at least one microneedle whereby the encapsulated vaccine retains bioactivity after cellular uptake.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2022
From: D'SOUZA, MARTIN J.
To: THE CORPORATION OF MERCER UNIVERSITY
Reel/Frame 060233/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2016
From: D'SOUZA, MARTIN J
To: THE CORPORATION OF MERCER UNIVERSITY
Reel/Frame 037860/0762 →
Continuity (3)
Continuation In Part 12569867 · Sep 29, 2009
Provisional Application 61100886 · Sep 29, 2008
Related Publication 20170042987A1 · Feb 16, 2017
Cited By (2)
US 12,491,290 US 12,708,750